- Home
- BAND vs ERAS Comparison
BAND vs ERAS Comparison
Compare BAND & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAND
- ERAS
- Stock Information
- Founded
- BAND 2000
- ERAS 2018
- Country
- BAND United States
- ERAS United States
- Employees
- BAND N/A
- ERAS N/A
- Industry
- BAND Computer Software: Prepackaged Software
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BAND Technology
- ERAS Health Care
- Exchange
- BAND Nasdaq
- ERAS Nasdaq
- Market Cap
- BAND 473.2M
- ERAS 439.7M
- IPO Year
- BAND 2017
- ERAS 2021
- Fundamental
- Price
- BAND $16.17
- ERAS $2.43
- Analyst Decision
- BAND Buy
- ERAS Buy
- Analyst Count
- BAND 6
- ERAS 6
- Target Price
- BAND $20.80
- ERAS $3.83
- AVG Volume (30 Days)
- BAND 279.0K
- ERAS 2.3M
- Earning Date
- BAND 10-30-2025
- ERAS 11-11-2025
- Dividend Yield
- BAND N/A
- ERAS N/A
- EPS Growth
- BAND N/A
- ERAS N/A
- EPS
- BAND N/A
- ERAS N/A
- Revenue
- BAND $758,106,000.00
- ERAS N/A
- Revenue This Year
- BAND $2.47
- ERAS N/A
- Revenue Next Year
- BAND $13.92
- ERAS N/A
- P/E Ratio
- BAND N/A
- ERAS N/A
- Revenue Growth
- BAND 14.51
- ERAS N/A
- 52 Week Low
- BAND $11.33
- ERAS $1.01
- 52 Week High
- BAND $23.00
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- BAND 46.42
- ERAS 73.25
- Support Level
- BAND $15.68
- ERAS $2.21
- Resistance Level
- BAND $16.62
- ERAS $2.65
- Average True Range (ATR)
- BAND 0.66
- ERAS 0.21
- MACD
- BAND -0.25
- ERAS 0.06
- Stochastic Oscillator
- BAND 16.71
- ERAS 89.39
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.